The objective of this study was to evaluate the evidence on cost‐effectiveness of
pharmacogenetic (PGx)–guided treatment for drugs with Clinical Pharmacogenetics …

The field of pharmacogenomics (PGx) is gradually shifting from the reactive testing of single
genes toward the proactive testing of multiple genes to improve treatment outcomes, reduce …

Pharmacogenetics (PGx) has the potential to personalize pharmaceutical treatments. Many
relevant gene–drug associations have been discovered, but PGx-guided treatment needs to …

Nowadays, many relevant drug–gene associations have been discovered, but
pharmacogenomics (PGx)-guided treatment needs to be cost-effective as well as clinically …

Warfarin pharmacogenomics has been an extensively studied field in the last decades as it
is focused on personalized therapy to overcome the wide interpatient warfarin response …

In recent years, the translation of genomic discoveries into mainstream medical practice and
public health has gained momentum, facilitated by the advent of new technologies …

Evidence of the value of pharmacogenomic testing is needed to inform policymakers and
clinicians for decision making related to adoption and coverage, and to facilitate …

Genomic medicine has greatly matured in terms of its technical capabilities, but the diffusion
of genomic innovations worldwide faces significant barriers beyond mere access to …

Background Genetic testing has potential roles in identifying whether an individual would
have risk of adverse drug reactions (ADRs) from a particular medicine. Robust cost …

Clopidogrel is an antiplatelet drug given to patients before and after having a percutaneous
coronary intervention (PCI). Genomic variants in the CYP2C19 gene are associated with …